Fig. 6

Peripheral inhibition of JMJD3 does not affect chronic pain response. (A, B) schematics showing the modified experimental procedure based on the complete Freund’s adjuvant (CFA)-induced chronic inflammatory pain. To induce peripheral inhibition of JMJD3, GSK-J4 was intrathecally (i.t.) injected during day 8 to day 13 into L4-L6 of 4-months old male and female C57BL/6mice (A). To induce temporary inhibition of JMJD3, GSK-J4 was intraperitoneally (i.p.) injected at day 8 and day 9 right before the pain recovery occurs (B). Dimethyl sulfoxide was injected as Vehicle. (C, D) No difference was found by peripheral inhibition of JMJD3 in male or female mice undergoing CFA-induced chronic inflammatory pain. N = 4 mice. Data represent mean ± SEM. Ns = not significant; two-way ANOVA with Sidak’s multiple comparisons test